Venous disease and COVID-19
Three cases of acute venous thromboembolism in females after vaccination for coronavirus disease 2019

https://doi.org/10.1016/j.jvsv.2021.07.009Get rights and content

Abstract

Since December 2020, four vaccines for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) have been developed, and three have been approved for immediate use in the United States. Two are mRNA vaccines, and one uses a viral vector mechanism. Thrombotic complications have been reported after vaccine administration, which were primarily cerebral sinus thromboses after administration of the viral vector vaccines. To the best of our knowledge, we are the first to report venous thrombotic complications within days of administration of the mRNA-1273 (Moderna) vaccine. We present a series of three women who developed venous thromboembolism after RNA-1273 vaccination at a single healthcare system.

Keywords

COVID-19
Deep vein thrombosis
Pulmonary embolism
Venous thromboembolism

Cited by (0)

This research was supported in part by the National Heart, Lung, and Blood Institute, United States (grant 5T32HL0098036 to E.A.A.). The University of Pittsburgh, United States holds a Physician-Scientist Institutional Award from the Burroughs Wellcome Fund (to E.A.A.).

Author conflict of interest: none.

The editors and reviewers of this article have no relevant financial relationships to disclose per the Journal policy that requires reviewers to decline review of any manuscript for which they may have a conflict of interest.

View Abstract